eoc317

EOC317 (also known as ACTB-1003 and EDP317) is an orally available small molecule multi-mode kinase inhibitor with potential antineoplastic activity. It targets and inhibits several kinases implicated in tumor growth and angiogenesis, including phosphatidylinositol 3 kinase (PI3K), fibroblast growth factor receptor (FGFR1), angiopoietin-1 receptor (TIE2), and vascular endothelial growth factor receptor 2 (VEGFR2). By inhibiting these kinases, EOC317 may induce apoptosis in tumor cells where these pathways are overexpressed. The drug was developed for the treatment of various solid tumors but has been discontinued after phase 1 clinical trials[1][2][3][4][5].

Other names

multi-mode kinase inhibitor eoc317